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tients with large anterior STEMI undergoing primary percutaneous
coronary intervention.
METHODS Participants from the INFUSE-AMI trial were categorized
according to smoking status at clinical presentation (current or prior
smoking vs. no history of smoking). The primary imaging endpoint
was cardiac magnetic resonance (MRI) assessed IS (% of left ven-
tricular mass) at 30 days. The secondary MRI endpoint was the
percentage of microvascular obstruction (MVO) of total myocardial
mass at 5 days and the total stunning and remodeling index (SRI) at
30 days. SRI was classiﬁed as worse (-1), absence of (0), mild (þ1)
and marked left ventricular function recovery ( þ2). The second-
ary endpoint was the rate of MACE at 1 year, deﬁned as the com-
posite of death, reinfarction, new-onset heart failure, or re-
hospitalization.
RESULTS Out of 447 patients enrolled in the INFUSE-AMI trial, 271
(60.6%) were current or past smokers, of whom 206 (76%) were
current smokers at the time of clinical presentation. Compared with
nonsmokers, smokers were younger and had a lower prevalence of
clinical comorbidities. At 30 days, there was no difference in me-
dian IS between smokers and nonsmokers (16.8% vs. 17.4%;
p¼0.67). However, smokers had lower median MVO of total
myocardial mass at 5 days (0.1% vs. 1.5%; p¼0.04) and higher 30-
day mean stunning and remodeling index (1.83.2 vs. 0.92.1;
p¼0.03). At 1 year, smokers had lower rates of MACE (4.5% vs.
9.7%; p¼0.03). After multivariable adjustment for baseline con-
founders, smoking status had no effect on 30-day IS (standard er-
ror: 1.04; p¼0.42) or 1-year MACE (adjusted hazard ratio: 0.74; 95%
conﬁdence interval: 0.39–1.41; p¼0.36).
CONCLUSIONS In the INFUSE-AMI trial, smoking status had no effect
on MRI IS at 30 days compared with patients without a history of
smoking. Smokers exhibited lower total myocardial mass MVO and
better left ventricular recovery. Finally, while smokers had lower 1-
year MACE rates in the unadjusted analysis, this association was lost
following adjustment for baseline confounders.
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BACKGROUND Large randomized trials have failed to show a bene-
ﬁcial effect of statin treatment in chronic heart failure (HF). The in-
vestigators tried to evaluate the long-term effects of statin therapy in
patients with new onset HF following acute myocardial infarction
(AMI).
METHODS Between 2008 and 2011, we studied 1,055 patients with
AMI who had newly developed severe acute HF [left ventricular
ejection fraction  40%] and were discharged alive. The patients were
divided into two groups, a statin group (n ¼ 756) and a no-statin group
(n ¼ 299). We investigated the one-year major adverse cardiovascular
events (MACEs) and survival rate of each group. We then performed a
propensity-score matched analysis.
RESULTS In the original cohort, one-year MACEs (all-cause mortality,
MI, and any revascularization) were similar between the two groups
(16.5% vs. 14.7% in the statin or no-statin groups; p ¼ 0.47). Pro-
pensity-score matching yielded 256 pairs, and in that population we
observed comparable results in terms of MACEs (18.0% vs. 12.5% in
the statin or no-statin groups, p ¼ 0.11) and mortality (5.1% vs. 3.5% in
the statin or no-statin groups, p ¼ 0.51) (Table). Cox-regression anal-
ysis revealed that statin therapy was not an independent predictor for
occurrence of a MACE [Hazard ratio (HR) 1.11, 95% CI 0.79-1.57, p ¼
0.54] or all-cause mortality (HR 1.42, 95% CI 0.75-2.70, p ¼ 0.28)
(Figure).Total populationp valuePropensity-matched populationp value
No Statin
(n[299)Statin
(n[756)No Statin
(n[256)Statin
(n[256)Overall MACE* 44 (14.7%) 125 (16.5%) 0.47 32 (12.5%) 46 (18.0%) 0.11All-cause mortality 12 (4.0%) 43 (5.7%) 0.27 9 (3.5%) 13 (5.1%) 0.51Cardiac death 9 (3.0%) 32 (4.2%) 0.35 6 (2.3%) 9 (3.5%) 0.60Non-cardiac death 3 (1.0%) 11 (1.5%) 0.56 3 (1.2%) 4 (1.6%) 0.99Myocardial infarction 6 (2.0%) 16 (2.1%) 0.91 6 (2.3%) 5 (2.0%) 0.99Repeated
Revascularization24 (8.0%) 55 (7.3%) 0.68 17 (6.6%) 23 (9.0%) 0.41TLR 12 (4.0%) 28 (3.7%) 0.81 10 (3.9%) 13 (5.1%) 0.67TVR 4 (1.3%) 8 (1.1%) 0.70 4 (1.6%) 2 (0.8%) 0.69CABG 2 (0.7%) 6 (0.8%) 0.83 1 (0.4%) 0 (0%) 0.99Stent thrombosis 1 (0.3%) 7 (0.9%) 0.32 1 (0.4%) 5 (2%) 0.22*Composed of all-cause mortality, myocardial infarction and repeated revascularization.
CABG, coronary artery bypass grafting; CI, conﬁdence interval; HR, hazard ratio; MACE, major adverse
cardiovascular event; TLR, target-lesion revascularization; TVR, target-vessel revascularizationCONCLUSIONS Statin therapy did not reduce the long-term occur-
rence of MACEs or mortality in survivors of AMI with severe acute HF.
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BACKGROUND The recently published Trial of Routine Aspiration
Thrombectomy with PCI versus PCI Alone in Patients with STEMI
(TOTAL) has refuted the salutary effect of aspiration thrombectomy
(AT) in primary percutaneous coronary intervention (PPCI) for pa-
tients with ST-elevation myocardial infarction (STEMI). We sought to
perform an updated meta-analysis to assess clinical outcomes with AT
prior to PPCI compared with conventional PPCI alone due to the
availability of additional trial data.
METHODS All clinical trials (n¼20) that randomized patients
(n¼20,868) with STEMI between AT (n¼10,458) and PPCI (n¼10,410)
were included in this study.
